Ralph WÃ¤sch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2784156/publications.pdf

Version: 2024-02-01

102	3,374	201385	155451
papers	citations	27 h-index	55 g-index

105	105	105	4859
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia, 2015, 29, 2062-2068.	3.3	455
2	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 2018, 24, 282-291.	15.2	216
3	APC-dependent proteolysis of the mitotic cyclin Clb2 is essential for mitotic exit. Nature, 2002, 418, 556-562.	13.7	212
4	A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica, 2017, 102, 910-921.	1.7	187
5	Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica, 2016, 101, 1110-1119.	1.7	145
6	Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene, 2005, 24, 1-10.	2.6	119
7	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica, 2018, 103, 197-211.	1.7	110
8	The emerging role of APC/CCdh1 in controlling differentiation, genomic stability and tumor suppression. Oncogene, 2010, 29, 1-10.	2.6	107
9	The ubiquitin ligase APCCdh1 is required to maintain genome integrity in primary human cells. Oncogene, 2008, 27, 907-917.	2.6	105
10	Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MMâ€“comorbidity score. Blood Cancer Journal, 2011, 1, e35-e35.	2.8	96
11	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia, 2018, 32, 1697-1712.	3.3	83
12	Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for Outcome. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 541-551.	0.2	72
13	Cardiovascular adverse events in modern myeloma therapy â€“ Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica, 2018, 103, 1422-1432.	1.7	70
14	Ruxolitinib. Recent Results in Cancer Research, 2018, 212, 119-132.	1.8	66
15	<scp>CXCL</scp>12 and <scp>CXCR</scp>7 are relevant targets to reverse cell adhesionâ€mediated drug resistance in multiple myeloma. British Journal of Haematology, 2017, 179, 36-49.	1.2	63
16	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 Ã— 2, Phase II Trial. Journal of Clinical Oncology, 2020, 38, 257-270.	0.8	63
17	Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood, 2018, 131, 1464-1475.	0.6	57
18	Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica, 2019, 104, 370-379.	1.7	53

#	Article	IF	Citations
19	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leukemia and Lymphoma, 2010, 51, 1424-1443.	0.6	49
20	Current developments in immunotherapy in the treatment of multiple myeloma. Cancer, 2018, 124, 2075-2085.	2.0	49
21	Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica, 2020, 105, 1183-1188.	1.7	46
22	Prognostic Factor and Quality of Life Analysis in 160 Patients Aged â‰¥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 967-975.	2.0	42
23	Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. Journal of Internal Medicine, 2019, 286, 63-74.	2.7	42
24	A Novel GVHD-Prophylaxis with Low-Dose Alemtuzumab in Allogeneic Sibling or Unrelated Donor Hematopoetic Cell Transplantation: The Feasibility of Deescalation. Biology of Blood and Marrow Transplantation, 2009, 15, 1563-1570.	2.0	40
25	Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. Haematologica, 2020, 105, 2872-2878.	1.7	40
26	Ruxolitinibâ€“ECP combination treatment for refractory severe chronic graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 909-916.	1.3	32
27	The role of APC/CCdh1 in replication stress and origin of genomic instability. Oncogene, 2016, 35, 3062-3070.	2.6	29
28	Cell cycle control in acute myeloid leukemia. American Journal of Cancer Research, 2012, 2, 508-28.	1.4	29
29	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. Haematologica, 2021, 106, 2054-2065.	1.7	27
30	Strong inducible knockdown of APC/C^{Cdc20}does not cause mitotic arrest in human somatic cells. Cell Cycle, 2009, 8, 643-646.	1.3	25
31	BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1). Recent Results in Cancer Research, 2010, 184, 215-218.	1.8	23
32	BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy. Haematologica, 2013, 98, 1886-1895.	1.7	21
33	Novel immunotherapies in multiple myeloma â€“ chances and challenges. Haematologica, 2021, 106, 2555-2565.	1.7	21
34	Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation. Bone Marrow Transplantation, 2013, 48, 1098-1103.	1.3	20
35	Stevensâ€“Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. Annals of Hematology, 2012, 91, 287-289.	0.8	19
36	Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials. Leukemia and Lymphoma, 2018, 59, 2692-2699.	0.6	19

#	Article	IF	Citations
37	Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2018, 24, 2277-2284.	2.0	19
38	Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with longâ€term followâ€up of 815 patients. Cancer, 2020, 126, 3504-3515.	2.0	18
39	Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit) Tj ETQq1 1 0.784314 rgBT /Overlock	1.3	
40	Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation. Annals of Hematology, 2001, 80, 201-208.	0.8	16
41	Monitoring APC/C activity in the presence of chromosomal misalignment in unperturbed cell populations. Cell Cycle, 2012, 11, 310-321.	1.3	16
42	Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis. Annals of Hematology, 2021, 100, 2339-2350.	0.8	16
43	Geriatric assessments and frailty scores in multiple myeloma patients. Current Opinion in Oncology, 2021, Publish Ahead of Print, 648-657.	1.1	16
44	Radiation-Free Allogeneic Conditioning with Fludarabine, Carmustine, and Thiotepa for Acute Lymphoblastic Leukemia and Other Hematologic Malignancies Necessitating Enhanced Central Nervous System Activity. Biology of Blood and Marrow Transplantation, 2012, 18, 1430-1437.	2.0	15
45	Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo. Oncotarget, 2017, 8, 21153-21166.	0.8	15
46	Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Leukemia Research, 2015, 39, 462-470.	0.4	14
47	Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica, 2021, 106, 875-880.	1.7	14
48	Two cases of carfilzomibâ€induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. BMC Nephrology, 2021, 22, 32.	0.8	14
49	Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. Leukemia and Lymphoma, 2017, 58, 1849-1858.	0.6	13
50	Up-regulation ofRUNX2in acute myeloid leukemia in a patient with an inherentRUNX2haploinsufficiency and cleidocranial dysplasia. Leukemia and Lymphoma, 2014, 55, 1930-1932.	0.6	12
51	Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia. Leukemia, 2020, 34, 1154-1157.	3.3	12
52	Time from first symptom onset to the final diagnosis of multiple myeloma (MM) â€“ possible risks and future solutions: retrospective and prospective â€˜Deutsche Studiengruppe MMâ€™ (DSMM) and â€˜European Myeloma Networkâ€™ (EMN) analysis. Leukemia and Lymphoma, 2020, 61, 875-886.	0.6	12
53	Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation. Journal of Geriatric Oncology, 2021, 12, 521-530.	0.5	12
54	Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia. Bone Marrow Transplantation, 2021, 56, 841-852.	1.3	12

#	Article	IF	Citations
55	First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL). Blood, 2021, 138, 362-362.	0.6	12
56	Allogeneic Stem Cell Transplantation in Multiple Myeloma. Cancers, 2022, 14, 55.	1.7	12
57	Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors. Cancers, 2021, 13, 4320.	1.7	11
58	Pomalidomide. Recent Results in Cancer Research, 2014, 201, 359-372.	1.8	11
59	Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?. Haematologica, 2016, 101, 1276-1278.	1.7	10
60	Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma. Haematologica, 2020, 105, e523.	1.7	10
61	The Role of the APC/C and Its Coactivators Cdh1 and Cdc20 in Cancer Development and Therapy. Frontiers in Genetics, 0, 13, .	1.1	10
62	Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort. Cancer, 2021, 127, 3422-3436.	2.0	9
63	The impact of pulmonary function in patients undergoing autologous stem cell transplantation. Blood Advances, 2021, 5, 4327-4337.	2.5	9
64	Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 110-120.	1.3	8
65	Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial.. Journal of Clinical Oncology, 2018, 36, 8019-8019.	0.8	8
66	Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia. Oncotarget, 2016, 7, 48220-48230.	0.8	8
67	Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients â©¾60 years with advanced AML/MDS. Leukemia, 2016, 30, 2426-2429.	3.3	7
68	Teaming up for CAR-T cell therapy. Haematologica, 2019, 104, 2335-2336.	1.7	7
69	Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment. Haematologica, 2020, 105, 859-861.	1.7	7
70	Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients. Frontiers in Oncology, 2021, 11, 708231.	1.3	7
71	Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1045-1055.	1.2	7
72	Targeting mitotic exit for cancer treatment. Expert Opinion on Therapeutic Targets, 2011, 15, 785-788.	1.5	6

#	Article	IF	Citations
73	Trained clinical nurse specialists proficiently obtain bone marrow aspirates and trephine biopsies in a nearly painless procedureâ€"a prospective evaluation study. Annals of Hematology, 2015, 94, 1577-1584.	0.8	6
74	The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. European Journal of Haematology, 2017, 99, 449-458.	1.1	6
75	Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. Haematologica, 2018, 103, 755-758.	1.7	6
76	Pomalidomide. Recent Results in Cancer Research, 2018, 212, 169-185.	1.8	6
77	The 3' Untranslated Region of the Cyclin B mRNA Is Not Sufficient to Enhance the Synthesis of Cyclin B during a Mitotic Block in Human Cells. PLoS ONE, 2013, 8, e74379.	1.1	6
78	PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion. Leukemia, 2019, 33, 1296-1301.	3.3	5
79	APC/CCdh1 regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells. Cellular and Molecular Life Sciences, 2019, 76, 369-380.	2.4	5
80	Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient. Haematologica, 2020, 105, e138-e140.	1.7	5
81	Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule. Leukemia and Lymphoma, 2018, 59, 1722-1725.	0.6	4
82	Interdisciplinary approach to multiple myeloma â€“ time to diagnosis and warning signs. Leukemia and Lymphoma, 2021, 62, 891-898.	0.6	4
83	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. Cancer, 2021, 127, 3413-3421.	2.0	4
84	Aggressive plasmablastic lymphoproliferation complicated by hemophagocytic syndrome 12 years after heart transplant. Leukemia and Lymphoma, 2012, 53, 1845-1848.	0.6	3
85	Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?. Haematologica, 2019, 104, 2128-2131.	1.7	3
86	Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures. BMC Cancer, 2021, 21, 173.	1.1	3
87	Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation. Blood, 2016, 128, 2247-2247.	0.6	3
88	Carfilzomib. Recent Results in Cancer Research, 2018, 212, 265-283.	1.8	2
89	Dapsone-Induced Hemolytic Anemia in Multiple Myeloma: Case Report of Various Differential Diagnoses. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e821-e825.	0.2	2
90	A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT. Annals of Hematology, 2021, 100, 2095-2103.	0.8	2

#	Article	IF	Citations
91	Proteasome inhibition: the dawn of novel therapies in multiple myeloma. Haematologica, 2022, 107, 1018-1019.	1.7	2
92	Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations. Journal of Visualized Experiments, 2012, , e4239.	0.2	1
93	GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study. Clinical and Experimental Nephrology, 2019, 23, 199-206.	0.7	1
94	Case Report: Refusal of an Veno-Arterial Extracorporeal Membrane Oxygenation Due to Malignant Disease? â€" An Extremely Rare Form of Cardiac Involvement in Acute Myeloid Leukemia. Frontiers in Medicine, 2021, 8, 584507.	1.2	1
95	Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab. Annals of Hematology, 2021, 100, 1637-1640.	0.8	1
96	Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial. Blood, 2020, 136, 9-10.	0.6	1
97	A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin. Leukemia and Lymphoma, 2022, 63, 2260-2262.	0.6	1
98	Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract. Bone Marrow Transplantation, 0, , .	1.3	1
99	The Use of SNAP Labeling to Study Cell Cycle Oscillatory Proteins. Methods in Molecular Biology, 2016, 1342, 201-208.	0.4	0
100	In search of the optimal proteosome inhibitor. How, when and for whom?. Haematologica, 2021, 106, 2539-2541.	1.7	0
101	Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis. Blood, 2016, 128, 5979-5979.	0.6	0
102	Targeting mitotic exit in solid tumors. American Journal of Cancer Research, 2021, 11, 3698-3710.	1.4	0